Archived Monthly Oncology Tumor Boards: Management of Advanced Ovarian Cancer
Due to the rapidly changing treatment landscape, clinicians in the community who treat advanced ovarian cancer may not be aware of new data. In order to optimize clinical outcomes, it is crucial for clinicians to be educated on this topic to ensure that they select the most appropriate treatment options for their patients with ovarian cancer.
Category
- Ovarian Cancer
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates in Ovarian Cancer - Putting Together the PARP Puzzle and Understanding a New Therapeutic Target
The flurry of changes to the PARPi indications can cause considerable confusion in clinical practice. It may be difficult for health care professionals to keep track of the emerging data and understand how to apply it to patient care. It is important that health care professionals, including pharmacists, are able to educate their patients on the risks vs. benefits of these agents to help empower them to make informed decisions regarding their treatment.
Category
- Ovarian Cancer
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
NCCN Guidelines® Insights - Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
Category
- Ovarian Cancer
Format
- Monograph/Journal Supplement
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation